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OBJECTIVES We sought to assess hydroquinidine (HQ) efficacy in selected patients with Brugada
syndrome (BrS).
BACKGROUND Management of asymptomatic patients with BrS and inducible arrhythmias remains a key
issue. Effectiveness of class Ia antiarrhythmic drugs, which inhibit the potassium transient
outward current of the action potential, has been suggested in BrS.
METHODS From a cohort of 106 BrS patients, we studied 35 who received HQ (32 men; mean age 48
 11 years). Patients had asymptomatic BrS and inducible arrhythmia (n  31) or multiple
appropriate shocks from an implantable cardioverter-defibrillator (ICD) (n  4). Asymp-
tomatic patients with inducible arrhythmia underwent electrophysiologic (EP)-guided ther-
apy. When ventricular tachycardia (VT)/ventricular fibrillation (VF) inducibility was not
prevented, or in case of HQ intolerance, an ICD was placed.
RESULTS Hydroquinidine prevented VT/VF inducibility in 76% of asymptomatic patients who
underwent EP-guided therapy. Syncope occurred in two of the 21 patients who received
long-term (17  13 months) HQ therapy (1 syncope associated with QT interval
prolongation and 1 unexplained syncope associated with probable noncompliance). In
asymptomatic patients who received an ICD (n 10), one appropriate shock occurred during
a follow-up period of 13  8 months. In patients with multiple ICD shocks, HQ prevented
VT/VF recurrence in all cases during a mean follow-up of 14  8 months.
CONCLUSIONS Hydroquinidine therapy prevented VT/VF inducibility in 76% of asymptomatic patients with
BrS and inducible arrhythmia, as well as VT/VF recurrence in all BrS patients with multiple
ICD shocks. These preliminary data suggest that preventive treatment by HQ may be an
alternative strategy to ICD placement in asymptomatic patients with BrS and inducible
arrhythmia. (J Am Coll Cardiol 2004;43:1853–60) © 2004 by the American College of
Cardiology Foundationc
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nhe Brugada syndrome (BrS) is an inherited arrhythmo-
enic disease associated with a risk of sudden cardiac death
ue to ventricular fibrillation (VF) (1). The proposed
echanism of the arrhythmia and ST-segment elevation
nvolves imbalance between the inward (INa and ICa) and
utward currents, mainly the transient outward current (Ito),
t the end of phase 1 of the epicardial action potential (2,3).
ecause of the high rate of recurrence of the arrhythmic
vents and because no drug was found to be effective,
atients rescued from sudden cardiac death or those who
xperienced syncope are candidates for an implantable
ardioverter-defibrillator (ICD) (4,5). In asymptomatic pa-
ients diagnosed at random or after a family inquiry, risk
tratification is not clearly established. According to Bru-
ada, a spontaneous coved-type electrocardiographic
ECG) pattern and ventricular tachycardia (VT) or VF
nducibility during electrophysiologic (EP) study are predic-
ive of a poor outcome (5). Patients will experience an
rrhythmic event in 17% of the cases during a mean
ollow-up of 27 months. Updated results showed that
symptomatic patients with inducible arrhythmia will have
n arrhythmic event in 12% of the cases during a follow-up
f 31 months, regardless of the presence of a spontaneous
From the *Amiens-Picardie University Hospital, Amiens; †Lariboisie`re University
ospital, Paris; and ‡Inserm U582, Pitie´-Salpeˆtrie`re Hospital, Paris, France.
Manuscript received October 2, 2003; revised manuscript received November 22,i003, accepted December 9, 2003.oved-type ECG (6). The predictive value of other markers
s not established. The presence of familial sudden cardiac
eath is not associated with an increased risk, and there was
nly a trend toward a worse prognosis in males than in
emales (p  0.07) (5). Consequently, in the absence of
nother recognized option, prophylactic placement of an
CD in asymptomatic subjects with inducible arrhythmia
nd spontaneous coved-type ECG of BrS was proposed
5,7). Nevertheless, VT/VF inducibility has been found to
e a poor predictor of the recurrence of arrhythmic events in
ymptomatic patients in two reports (8,9). A recent inter-
ational consensus emphasized the lack of conclusive evi-
ence to guide risk stratification in asymptomatic patients
ith BrS (10). The management of asymptomatic patients
ith BrS remains a key issue. The therapeutic options are
ither a prophylactic ICD, with the issue of long-term
anagement of the ICD, or no treatment at all, with the
isk of sudden cardiac death as a first symptom.
In 1999, Belhassen et al. (11) observed that class I
ntiarrhythmic agents, which inhibit Ito (mainly quinidine),
revented arrhythmia induction, as well as arrhythmia
ecurrences, in a long-term follow-up in four of five cardiac
rrest survivors with BrS. At the same time, quinidine
fficacy was mentioned in isolated cases, including pediatric
atients with incessant polymorphic VT (12,13). Also,
ormalization of the ST-segment was described with quin-dine (14). As quinidine appeared to be a valuable drug in
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Hydroquinidine Therapy in BrS May 19, 2004:1853–60ymptomatic patients, we assumed that it may also represent
pharmacologic option in asymptomatic patients.
The aim of this study was to report our experience with
ydroquinidine (HQ) in selected patients with BrS, espe-
ially in asymptomatic patients with inducible arrhythmia.
ETHODS
tudy population. The entire BrS population followed in
ur institutions (University Hospital of Amiens-Picardie,
miens, and Lariboisie`re University Hospital, Paris) in-
ludes 106 patients. These patients had documented symp-
omatic VT/VF in 13 cases, unexplained syncope in 13
ases, and no symptoms in the 80 remaining cases (Fig. 1).
Abbreviations and Acronyms
BrS  Brugada syndrome
ECG  electrocardiogram
EP  electrophysiologic
HQ  hydroquinidine
ICD  implantable cardioverter-defibrillator
Ito  transient outward current
VF  ventricular fibrillation
VT  ventricular tachycardia
igure 1. Brugada syndrome (BrS) population. Among the BrS cohort
ydroquinidine therapy was prescribed to asymptomatic patients with BrS
ot treated, except in case of multiple familial sudden deaths. In case o
lectrophysiologic (EP) study was not performed. The study population a
efibrillator (ICD) shocks. SD  sudden death; VF  ventricular fibrillation.In this population, HQ therapy has been systematically
nd prospectively used since 1999 in asymptomatic patients
ith BrS and inducible arrhythmia (n  31) and in
ymptomatic patients with BrS who experienced multiple
ppropriate ICD discharges (n  4). The study population
Table 1) includes 35 consecutive patients (32 men; mean
ge 48  11 years [range 18 to 76 years]).
Brugada syndrome was diagnosed in accordance with
urrent diagnosis criteria (10). In symptomatic patients or
ubjects with a familial history of BrS, diagnosis was based
n a coved-type pattern of ST-segment elevation in more
han one right precordial ECG lead (V1 to V3) in the
resence or absence of a sodium channel blocker. For
symptomatic patients with a saddle-type ECG, a
0.2-mV drug-induced coved ST-segment elevation in the
ight precordial leads was required. The absence of struc-
ural heart disease was verified by noninvasive and invasive
nvestigations, including two-dimensional echocardiogra-
hy, magnetic resonance imaging, and coronary angiogra-
hy with right and left ventricular angiography, as appro-
riate. Sodium channel blockade challenge was carried out
y ajmaline intravenous infusion (1 mg/kg/s). Ajmaline
hallenge was classified as positive if a 0.2-mV downslop-
ng ST-segment elevation measured 20 ms after the end of
wed in both institutions, 80 patients were asymptomatic. From 1999,
ducible arrhythmia (*) (n  31). In case of noninducibility, patients were
g-induced BrS with a normal baseline electrocardiogram (n  12), the
cludes four BrS patients (†) who had multiple implantable cardioverter-follo
and in
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May 19, 2004:1853–60 Hydroquinidine Therapy in BrShe QRS complex was observed in the right precordial lead,
ncluding V1 and V2 recorded in the second intercostal space
2,15). SCN5A mutations were present in five (28%) of the
8 patients who were genotyped.
A “slow-release” HQ preparation (HQ chlorhydrate;
erecor, Sanofi-Synthelabo Laboratory, Paris, France) was
iven at the standard dose of 300 mg twice a day. Modifi-
ations of the ECGs were compared immediately before
Q and after the beginning of the treatment in an attempt
o minimize the influence of spontaneous variation. The EP
tudies were repeated after a trial period of at least two
eeks. Hydroquinidine intake was increased to 900 mg/day
hen the patients were still inducible and had a plasma level
3 mol/l (the usual concentration by fluorimetry is 3 to 6
mol/l). A second EP study on HQ was proposed after dose
djustment. In case of noninducibility at HQ 600 mg/day,
he dose was maintained no matter what the HQ plasma
evel was.
lectrophysiologic study. Electrophysiologic study was per-
ormed (once written, informed consent was obtained) at
aseline and under HQ with a standardized protocol, including
driving cycle length at 600 and 400 ms, with up to three
xtrastimuli and a coupling interval until the refractory period
ut without repetition of extrastimulation. The right ventric-
lar apex and right ventricular outflow tract were paced at twice
he right ventricular diastolic threshold. Nonsustained VT was
efined as VT of more than six complexes. Inducibility of
T/VF was defined as the induction of monomorphic or
olymorphic VT lasting 20 s or degenerating into VF.
ecause of the usual irregularity of polymorphic VT, we chose
o define the VT cycle length as the mean cycle length of the
eats occurring during the first second of tachycardia. The
ight ventricular effective refractory period was measured at the
able 1. Study Population
BrS Patients
(n  35)
ge (yrs) 48  11 (18–76)
ale 32 (91%)
symptomatic BrS and inducible arrhythmia 31 (89%)
rS and multiple ICD shocks 4 (11%)
amilial form
None 22 (63%)
Familial BrS 7 (20%)
Familial SD 4 (11%)
Familial BrS and SD 2 (6%)
CG pattern
Coved 23 (66%)
Drug-induced 12 (34%)
RS duration (ms) 102  15
V interval (ms) 49  10
Tc interval (ms) 402  20
VERP (ms) 233  18
nduced VT cycle length (ms) 186  18
ata are presented as the mean value  SD (range) or number (%) of patients.
BrS  Brugada syndrome; ECG  electrocardiographic; ICD  implantable
ardioverter-defibrillator; RVERP  right ventricular effective refractory period; SD
sudden death; VT  ventricular tachycardia.ight ventricular apex and was defined as the longest S1S2 snterval that failed to evoke a ventricular response at a pacing
ycle length of 600 ms.
tatistics. Variables are expressed as the mean  SD.
orrelations between categorical variables were assessed by
he phi coefficient. This measure is similar to the correlation
oefficient in its interpretation. Phi compares the product of
he diagonal cells (a · d) to the product of the off-diagonal
ells (b · c) in a four-fold table. Two binary variables are
onsidered positively associated if most of the data fall along
he diagonal cells. In contrast, two binary variables are
onsidered negatively associated if most of the data fall off
he diagonal. The effects of HQ on the ECG and EP
ontinuous variables were assessed with the paired Student
tests. A value p  0.05 was considered as significant.
ESULTS
rial period with HQ (Fig. 2 and Table 2). The EP study
as repeated under HQ in 29 of the 31 asymptomatic
atients with BrS and inducible arrhythmia. A total of 20 of
he 29 asymptomatic patients were not inducible with 600
g/day HQ. Plasma levels were below the therapeutic value
n three of the nine patients who were still inducible.
ydroquinidine was increased to 900 mg/day, and VT/VF
ecame noninducible in two of these three cases. The third
atient refused an EP study at 900 mg/day. At last, HQ
revented VT/VF inducibility in 22 (76%) of 29 of the
symptomatic patients with BrS. The mean HQ plasma
evel was comparable in both groups: 2.7  1.3 mol/l in
oninducible patients and 2.8 1.6 mol/l in patients with
ersistent VT/VF inducibility.
Decreased or disappearance of ST-segment elevation on
he ECG occurred in 12 (34%) of 35 patients. There was no
orrelation between ST-segment modification and VT/VF
nducibility (phi coefficient  0.18, p  0.32). The cor-
ected QT (QTc) interval and QRS duration were slightly
ut significantly prolonged (Table 2).
During the first month of HQ therapy, drug intolerance
diarrhea) occurred in seven (20%) patients, leading to HQ
ithdrawal in two patients. A rise in hepatic enzymes
three-fold upper normal value of transaminase) associated
ith nausea and asthenia occurred after a week of treatment
n one patient. Hydroquinidine-induced hepatitis was re-
ersible after withdrawal of the treatment. These three
atients received an ICD.
ong-term treatment with HQ. Patients who were not
nducible with HQ and had a good tolerance, together with
he patient who refused the EP study (n  21) and the four
atients with BrS and multiple ICD shocks, received
ong-term treatment (Fig. 2).
In the 21 asymptomatic patients with BrS and inducible
rrhythmia, 17 (81%) were asymptomatic after 17  13
onths of follow-up. Two patients had to stop HQ at the
econd and fifth month, respectively, for troublesome diar-
hea and received an ICD. Two other patients experienced
yncope during follow-up (Table 3). The first patient was 51
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Hydroquinidine Therapy in BrS May 19, 2004:1853–60ears old and experienced two short syncopal episodes at
ork, 12 months after the beginning of HQ at the dose of
00 mg/day. The plasma HQ level was not measured on
rrival, and the QTc interval was 409 ms. The plasma HQ
igure 2. Electrophysiologically guided therapy. After a trial period w
symptomatic patients with BrS and inducible arrhythmia, 29 underwen
brillation (VF) noninducibility was 76% (22 of 29). Abbreviations as in
able 2. Hydroquinidine in Patients With Brugada Syndrome
HQ Therapy
Patients
(n  35) p Value*
ean dose (mg/day) 609  89
lasma level (mol/l) 2.7  3.3
ide effects
Diarrhea 7 (20%)
Treatment withdrawal 2 (5.7%)†
dverse drug reaction
Reversible hepatitis 1 (3%)
ffects on ECG and electrophysiologic
intervals
Delta QRS duration 13  12 0.001
Delta QTc interval 10  7 0.001
Delta HV interval 8  11 0.003
Delta RVERP 17  19 0.001
ffects on ECG pattern of BrS
Unchanged ECGs 23 (66%)
Normalization or reduction of ST-SE 12 (34%)
rogrammed ventricular stimulation
with HQ
29
Noninducible 22 (76%)
3 Repetitive beats 16
Nonsustained pVT (up to 20 s) 5
Nonsustained mVT (up to 20 s) 1
Sustained VF or pVT 7 (24%)
Delta VTCL (%) 17  17 0.006
By the paired t test. †Two other hydroquinidine withdrawals (second and fifth
onths) were necessary during the long-term period. Data are presented as the mean
alue  SD or number (%) of patients.
Delta  ECG variation under hydroquinidine; HQ  hydroquinidine; mVT 
onomorphic ventricular tachycardia; pVT  polymorphic VT; ST-SE  ST-
egment elevation; VF  ventricular fibrillation; VTCL  ventricular tachycardia
ycle length; other abbreviations as in Table 1. Aevel, measured after five days of hospitalization, was 4.65
mol/l, and simultaneously, the QTc interval was 447 ms.
o spontaneous ventricular arrhythmia could be docu-
ented during a 48-h period of ECG monitoring. Non-
ompliance was suspected due to a normal QTc interval on
rrival. Hydroquinidine was stopped, and an ICD was
nserted. No ICD discharge occurred during the one-year
ollow-up. The second patient was also 51 years old and had
diurnal sensation of tachycardia, dizziness, and then
yncope only one month after HQ was started. During
CG monitoring, runs of VT were recorded (Fig. 3). The
CG showed persistent downsloping ST-segment elevation
nd a negative T-wave in leads V1, V2, and V3. The QTc
nterval was prolonged to 530 ms, whereas it was only 425
s before treatment. This was the longest QTc interval
ecorded in all of the BrS patients treated with HQ. A QTc
500 ms was observed only in this patient. Kalemia was 3.6
droquinidine (HQ), BrS patients underwent EP study (EPS). Of 31
P study with HQ. The rate of ventricular tachycardia (VT)/ventricular
1.
able 3. Follow-Up
Follow-Up of Asymptomatic Patients With BrS and Inducible
Arrhythmia Receiving Long-Term Treatment With Hydroquinidine
umber of patients 21
ollow-up in months (range) 17  13 (1–42)
vents during follow-up 4
Digestive intolerance 2
Syncope associated with prolonged QTc interval 1
Unexplained syncope 1
CD placement 4
Follow-Up of Asymptomatic Patients With BrS and Inducible
Arrhythmia Who Received an ICD
umber of patients 10
ollow-up in months (range) 13  8 (3–28)
vents during follow-up
Appropriate shock 1ith hy
t an Ebbreviations as in Table 1.
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May 19, 2004:1853–60 Hydroquinidine Therapy in BrSEq/l, and the plasma HQ level was 4.6 mol/l. No
utation in SCN5A was identified. Hydroquinidine was
ithdrawn and an ICD was placed without any events
uring one-year follow-up. Two hypotheses could explain
he syncope in this patient: 1) a drug inefficacy resulting in
uns of VT; and 2) a possible proarrhythmic effect with HQ
reatment.
In the 10 asymptomatic patients with BrS and inducible
rrhythmia who received an ICD for persistent VT/VF
nducibility under HQ or for early drug intolerance, we
bserved one appropriate shock (polymorphic VT/VF) dur-
ng a follow-up of 13  8 months. The shock occurred
uring nocturnal sleep, four months after ICD placement in
45-year-old man who previously had digestive intolerance
ith HQ. Brugada syndrome had been recognized 17
onths earlier on a systematic 12-lead ECG. In another
atient, we also observed multiple inappropriate shocks due
o oversensing of the T-wave six months after implantation.
ead repositioning had to be performed.
The main clinical characteristics of the patients with BrS
nd multiple ICD shocks are summarized Table 4. In this
igure 3. (A) Major QTc interval prolongation observed in a patient who
as not found in this patient. Measurement of the QT interval includes th
2. (B) Monomorphic runs of VT were recorded in the emergency room,
f HQ during a follow-up of one year. Syncope may be attributed to a dru
s the absence of typical pause-dependent torsade de pointes and of a long c
rolongation. Abbreviations as in Figure 1.roup, no recurrences of shocks or VT/VF with HQ were Vvidenced when the ICD memories were checked. A
triking effect on runs of VT was documented in one patient
Fig. 4). None of these patients underwent programmed
entricular stimulation with HQ therapy.
ISCUSSION
he main results of this preliminary study are the following:
) HQ prevented VT/VF inducibility in 22 (76%) of the 29
symptomatic patients with BrS and inducible arrhythmia.
) During long-term HQ therapy (17  13 months), a
ocumented nonsustained VT associated with QTc prolon-
ation (QTc interval 530 ms) occurred in one (3.7%) of the
1 asymptomatic patients with BrS and inducible arrhyth-
ia. Also, an unexplained syncope was observed in a patient
n whom HQ compliance was uncertain. Improvement of
utcome with HQ therapy might be expected with careful
T interval surveillance. 3) During a follow-up of 13  8
onths, an appropriate shock was noted in one (10%) of the
0 patients who received an ICD. 4) In a patient with BrS
nd multiple ICD shocks, HQ prevented shocks and the
ncope only one month after the beginning of HQ. The SCN5A mutation
rted T wave observed after the downsloping ST-segment elevation in lead
n only one lead. No recurrence of syncope was observed after withdrawal
fficacy or to a proarrhythmic effect of HQ. The argument for drug failure
g interval. The argument for a proarrhythmic event is major QTc intervalhad sy
e inve
but i
g ine
ouplinT/VF episodes.
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Hydroquinidine Therapy in BrS May 19, 2004:1853–60ffects of HQ on VT/VF inducibility. In previous re-
orts, VT/VF inducibility in asymptomatic BrS patients
aried from 12% to 64% (5,16–18). We have, in our BrS
opulation, a rate at the upper limit (60%), which may be
xplained by two factors. First, according to recent recom-
endations (5,10), we have not investigated 12 patients
ith asymptomatic BrS and normal baseline ECGs. Induc-
bility is known to be low (18%) in this subpopulation of
rS (5). Then, it has been reported that VT/VF inducibility
s high when, as in our series, two pacing sites are used and
hen the shortest coupling interval reaches the refractory
eriods (18).
Prevention of VT/VF inducibility with quinidine in BrS
atients was first reported in 1999 by Belhassen et al. (11).
hese authors found after reassessment of a series of 34
atients with idiopathic VF treated with a class I antiar-
able 4. Clinical Characteristics of Patients With Multiple Impla
Patient
Number
Age
(yrs) Gender Symptoms ECG Type
Famil
Form
1 18 M Nocturnal SD Permanent,
coved-type
No
2 40 M Nocturnal SD Permanent,
coved-type
Familial
3 71 M Nocturnal SD Transient,
coved-type
Familial
4 42 M Nocturnal
syncope
Permanent,
coved-type
Familial
One shock with 600 mg/day.
EP  electrophysiological; M  male; other abbreviations as in Tables 1 and 2.
Control
10
8
6
4
2
0
N/min
18       20        22        0        2          4          6         8         10       
Heart rate
bpm
150
100
50
PVC
0
igure 4. Effect of HQ in one of the four patients with BrS and multiple
entricular arrhythmia after two days of treatment. Abbreviations as in Figure 1hythmic, mainly quinidine, that five patients had BrS.
hey pointed out that VT/VF inducibility had been pre-
ented in four (80%) of the five patients, a rate very close to
he rate found here (76%). This seems a meaningful result,
s these patients have a high reproducibility (85%) of their
aseline inducibility (19). Identically, it is important to note
hat, even if the clinical relevance of drug-induced suppres-
ion of VT/VF inducibility has been recently questioned in
redicting efficacy, especially in patients who have ischemic
eentry, the physiopathologic situation is different here. In
act, in patients with BrS, the purported arrhythmia mech-
nism is different (phase 2 re-entry) (2,3). Also, the left
entricular function, which is the main predictor of outcome
n patients with ischemic heart disease, is normal in BrS.
ffect of HQ on recurrence of arrhythmic events. The
esults obtained by Belhassen et al. (20) with quinidine were
le Cardioverter-Defibrillator Discharges
Baseline EP
Study
ICD Shocks
Before HQ
HQ Dose
(mg/day)
ICD Shocks
After HQ
Inducible 16 in 37 months 600 0 in 26 months
Not performed 30 in 7 years
and electrical
storm
600 0 in 12 months
Inducible 12 in 6 months 600 0 in 10 months
Inducible 6 in 4 months 600* then 900 0 in 10 months
Hydroquinidine: 600m
  14       16 h
10
8
6
4
2
0
N/min
12     14       16      18      20     22      0        2        4        6
Heart rate
bpm
PVC
150
100
50
0
hocks. Control  numerous salvoes of VT; HQ  dramatic reduction ofntab
ial
SD
BrS
SD12     
ICD s
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May 19, 2004:1853–60 Hydroquinidine Therapy in BrSecently updated. Their experience included seven cardiac
rrest survivors with a mean follow-up of 125 months. They
id not observe the recurrence of arrhythmic events in the
ix symptomatic patients treated with quinidine. The sev-
nth patient received an ICD because of extracardiac drug
ntolerance. High efficacy of quinidine has been also men-
ioned in isolated symptomatic cases (12,13). These obser-
ations are similar to the results observed here in the BrS
atients with multiple ICD shocks.
In contrast, no other drug has been found to be effective
n the clinical recurrence of the arrhythmic event, except a
eta-agonist (12) and cilostazol (21) in isolated cases of
lectrical storms. The Brugada brothers related their expe-
ience in patients treated with amiodarone and/or beta-
lockers in a study published in 1998 (4). The rates of an
rrhythmic event during a follow-up of 34 months were
imilar (30%) in patients treated with antiarrhythmic drugs
r with an ICD. Recently, the Defibrillator versus Beta-
lockers for Unexplained death in Thailand (DEBUT) trial
howed, in the sudden unexpected death syndrome, which
ncludes a majority of BrS, that ICD was superior to
eta-blockers in preventing sudden death (22). No mortality
as observed in the ICD group, as compared with a sudden
eath rate of 18% in the beta-blocker group.
ffects of HQ in asymptomatic patients with BrS and
nducible arrhythmia. Syncope occurred in 2 (9.5%) of the
1 asymptomatic patients with BrS and inducible arrhyth-
ia who received HQ during a follow-up of 17 months.
hese events were associated with a major QTc prolonga-
ion in one case and related to possible noncompliance in
nother patient. Based on an intention-to-treat analysis,
hey represent a failure of the treatment. Monitoring of the
Tc interval appears to be a useful tool to assess HQ
ardiac tolerance and compliance—both crucial determi-
ants. Syncope was observed in the only asymptomatic
atient with BrS and inducible arrhythmia who had QTc
nterval prolongation 500 ms. Major QTc interval pro-
ongation with HQ can occur in a subset of patients with
rS. QT interval prolongation and a BrS ECG pattern have
een reported in a family with the SCN5A mutation (23).
ny other genetic defect-producing action potential dura-
ion prolongation could also lead to the same phenotype
ith HQ treatment. We believe that in case of a major QTc
nterval prolongation, it is preferable to withdraw HQ.
onversely, when the QTc interval remains normal, non-
ompliance may be suspected and eventually confirmed by
he plasma level. Of note, quinidine bisulfate was used in
he Belhassen et al. (11) study and HQ chlorhydrate here.
s these two drugs are two different active forms with
ifferent active metabolites, their plasma values, as well as
heir mean doses, are not comparable. Careful control of the
Tc interval must be instituted in BrS patient receiving
Q and might improve the outcome of HQ therapy.
The rate of 10% (1 of 10 patients) of arrhythmic events
uring a period of 13 months in asymptomatic patients with
rS and inducible arrhythmia treated with a prophylacticCD is similar to the 12% rate of arrhythmic events
bserved in asymptomatic patients followed for 31 months
n the study from Brugada et al. (6), but our series had a
horter follow-up. Importantly, it is not appropriate to
onsider this group as a control group to assess the result of
Q therapy. First, treatment was not allocated after ran-
omization. Then, HQ prevented VT/VF inducibility in
atients receiving HQ, but not in patients treated with an
CD. This characteristic may be the consequence of differ-
nt forms of channel disease.
Q intolerance. In the work of Belhassen et al. (11),
uinidine was stopped in one case (14%) because of extra-
ardiac drug intolerance. Our experience is similar, with a
ate of 14% (5 of 35) of HQ interruptions for extracardiac
ide effects (gastrointestinal intolerance).
lectrocardiographic changes with quinidine. Normal-
zation of ST-segment elevation in BrS patients receiving
uinidine was first described in two patients by Alings et al.
14). In the 35 BrS patients treated with HQ, we observed a
eduction or normalization of the ECGs in 34% of cases. The
eduction or normalization of the ST segment with HQ
reatment was not correlated to prevention of VT/VF induc-
bility. This has been already described with one BrS patient
reated with disopyramide (24). Spontaneous variations of
T-segment elevation cannot be ruled out and possibility
ccounts, in part, for ST-segment modifications.
tudy limitations. The small number of patients, the short
ollow-up, and the absence of a control group and of ECG
ocumentation of clinical events in patients receiving HQ
ECG loop recorder) are the main limitations of this
reliminary study. Consequently, it is not adequate to
ecommend HQ therapy to all asymptomatic patients with
rS and inducible arrhythmia. A large, prospective, ran-
omized, controlled trial employing the protection of ICDs
s necessary to validate the true role of HQ in such a
opulation.
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